In the latest quarter, 21 analysts provided ratings for Regeneron Pharmaceuticals (NASDAQ:REGN), showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview ...

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...

Regeneron Pharmaceuticals, Inc. REGN and partner Sanofi SNY announced mixed results from two late-stage studies, AERIFY-1 and AERIFY-2, on itepekimab for the treatment of chronic obstructive ...

Regeneron Pharmaceuticals declined by 16.7 percent last week as investors sold off positions amid the surprising failure of ...

Sanofi (SNY) stock and Regeneron (REGN) stock fell after the companies reported mixed Phase 3 results for their COPD therapy ...

(REGN) stock drops 18% as trial data for COPD therapy developed with Sanofi (SNY) leads to a downgrade at Wells Fargo. Read ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

We recently published a list of These 10 Stocks Lost This Much Today. In this article, we are going to take a look at where ...

Key Takeaways The S&P 500 slipped less than 0.1% on Friday, May 30, 2025, as President Trump rekindled his tough rhetoric on ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has entered a key licensing agreement with Telesis Bio Inc. to integrate the ...

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically me ...

Human genetics testing firm 23andMe announced Tuesday it will voluntarily delist from the Nasdaq and deregister with the U.S.